| Synonyms: | |
| Status: | Phase 1 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | EX3O2Q61UV |
Structure
| InChI Key | YULUCECVQOCQFQ-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C26H19F3N4O |
| Molecular Weight | 460.46 |
| AlogP | 5.76 |
| Hydrogen Bond Acceptor | 4.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 4.0 |
| Polar Surface Area | 72.94 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 5.0 |
| Heavy Atoms | 34.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | 3-phosphoinositide dependent protein kinase-1 inhibitor | PubMed |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Kinase
Protein Kinase
AGC protein kinase group
AGC protein kinase PDK1 subfamily
|
- | 5000 | - | - | - |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Lymphoma | 1 | D008223 | ClinicalTrials |
Related Entries
Scaffolds
Cross References
| Resources | Reference |
|---|---|
| ChEBI | 131196 |
| ChEMBL | CHEMBL1650595 |
| EPA CompTox | DTXSID50225206 |
| FDA SRS | EX3O2Q61UV |
| Guide to Pharmacology | 8005 |
| PDB | M4J |
| PubChem | 10027278 |
| SureChEMBL | SCHEMBL570472 |
| ZINC | ZINC000003960083 |
CONTENTS